New diabetes combo aims to lower blood sugar in phase 3 trial
NCT ID NCT05028140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination called Piemonte association for people with type 2 diabetes whose blood sugar is not well controlled with current treatments. About 480 adults will receive either the new combination or a placebo to see if it safely lowers blood sugar levels. The main goal is to reduce glycated hemoglobin, a key measure of long-term blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE II DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
EMS
RECRUITINGHortolândia, São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New diabetes pill PS1 enters first human safety tests
- Can exercise protect diabetic joints? new study investigates
- Can a Heart-Healthy diet tame blood pressure in diabetes?
- Can doctor report cards boost care for millions with hypertension and diabetes?
- Heart scans may reveal hidden stroke risk in unexpected patients
- Heart fat melted by diabetes drugs? new MRI study investigates